Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018
Cited by 1,296 works. doi:10.1016/s0140-6736(18)31257-1
Authors
- Kohei Shitara
- Mustafa Özgüroğlu
- Yung‐Jue Bang
- Maria Di Bartolomeo
- Mario Mandalà
- Min‐Hee Ryu
- Lorenzo Fornaro
- Tomasz Olesiński
- Christian Caglevic
- Hyun Cheol Chung
- Kei Muro
- Eray Goekkurt
- Wasat Mansoor
- Ray McDermott
- Einat Shacham‐Shmueli
- Xinqun Chen
- Carlos Mayo
- Soonmo Peter Kang
- Atsushi Ohtsu
- Charles S. Fuchs
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- A Class of Rank Test Procedures for Censored Survival Data
- Comprehensive molecular characterization of gastric adenocarcinoma
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial